Econ­o­mists, health pol­i­cy ex­perts say J&J's IRA ar­gu­ments are 'over­ly sim­plis­tic'

A group of econ­o­mists and health pol­i­cy ex­perts from some of the coun­try’s top uni­ver­si­ties has called John­son & John­son’s chal­lenge to the In­fla­tion Re­duc­tion Act “over­ly sim­plis­tic and mis­lead­ing” in a new court fil­ing.

J&J In­no­v­a­tive Med­i­cine, pre­vi­ous­ly known as Janssen, is one of sev­er­al phar­ma­ceu­ti­cal com­pa­nies su­ing the fed­er­al gov­ern­ment over what they claim are vi­o­la­tions of the Con­sti­tu­tion in the IRA’s Medicare ne­go­ti­a­tion pro­vi­sions. The gov­ern­ment is weeks away from propos­ing what it says should be the max­i­mum fair price for the 10 drugs se­lect­ed for the first round of ne­go­ti­a­tions. While man­u­fac­tur­ers will have a month to pro­pose a coun­terof­fer, many have ar­gued that the ne­go­ti­a­tions are more akin to price con­trols.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER